Benjamin Hindson compensation by year
10x Genomics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $342,750 | $350,000 | $387,500 | $415,000 | $435,750 | $485,250 | $518,654 |
| Bonus | $24,635 | $0 | $108,500 | $151,176 | — | $0 | $0 |
| Stock awards | $0 | $0 | $1,985,401 | $4,724,102 | $2,607,754 | $3,634,816 | $1,793,155 |
| Option awards | $1,242,677 | $5,900,537 | $2,998,530 | $4,529,831 | $1,199,552 | $0 | $0 |
| Non-equity incentive | $59,124 | $0 | $0 | $0 | $182,574 | $150,000 | $292,950 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | — | $0 | $0 |
| All other | $0 | $264,974 | $0 | $49,780 | — | $0 | $0 |
| Total | $1,669,186 | $6,515,511 | $5,479,931 | $9,869,889 | $4,425,630 | $4,270,066 | $2,604,759 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 10x Genomics, Inc. DEF 14A filed April 24, 2026, accession 0001628280-26-027201, and prior-year filings. Open the filing on EDGAR.
How this page was built: the 10x Genomics, Inc. filed document, accession 0001628280-26-027201. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 90,402 | $1,474,457 | — |
| RSU | 67,655 | $1,103,453 | — |
| RSU | 39,985 | $652,155 | — |
| RSU | 20,089 | $327,652 | — |
| RSU | 18,194 | $296,744 | — |
| RSU | 11,847 | $193,225 | — |
| RSU | 11,371 | $185,461 | — |
| RSU | 1,780 | $29,032 | — |
| Option | 5,933 | — | $69.56 |
| Option | 12,686 | — | $33.67 |
| Option | 12,129 | — | $50.10 |
Per the Outstanding Equity Awards at Fiscal Year-End table in 10x Genomics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-24 | Sale | — | 13,818 | $63.02 | 488,182 |
| 2026-05-22 | Sale | — | 11,595 | $24.44 | 502,000 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
10x Genomics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Serge Saxonov | Chief Executive Officer | $6,329,244 |
| Eric Whitaker | Former Chief Legal Officer | $3,441,571 |
| Benjamin Hindson · this page | President and Chief Scientific Officer | $2,604,759 |
| Adam Taich | Chief Financial Officer | $2,233,107 |
Board service
10x Genomics board · FY2021–FY2025How this board is paid
Company policy: 10x Genomics pays directors a $60,000 cash retainer and $215,000 in RSUs. As stated in 10x Genomics's FY2024 proxy.
Benjamin Hindson's compensation dossier, 10x Genomics
You have read Benjamin Hindson's totals and holdings. The dossier adds each equity grant 10x Genomics disclosed for Benjamin Hindson and 10x Genomics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full 10x Genomics compensation record
free company briefThis page is one person within 10x Genomics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the 10x Genomics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order 10x Genomics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 10x Genomics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TXG
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.